• 1
    American Cancer Society. Cancer facts and figures, 2003. Available from URL: [accessed 16 Dec 2003].
  • 2
    Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol. 1985; 3: 827841.
  • 3
    Scher HI, Kelley WK. States and state transitions are all that really matter. J Urol. 2002; 168: 24512453.
  • 4
    Hartley-Asp B, Kruse E. Nuclear protein matrix as a target for estramustine-induced cell death. Prostate. 1986; 9: 387395.
  • 5
    Kreis W, Budman D, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol. 1997; 79: 192202.
  • 6
    Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusion in the treatment of metastatic breast cancer. J Clin Oncol. 1998; 16: 33533361.
  • 7
    Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000; 60: 18781886.
  • 8
    Markman M, Hall J, Spitz D, et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol. 2002; 20: 23652369.
  • 9
    Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter Phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2001; 19: 42164223.
  • 10
    Akerley W, Glantz M, Choy H, et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol. 1998; 16: 153158.
  • 11
    Vaughn DJ, Broome C, Hussain M, Gutheil JC, Markowitz AB. A Phase II trial of weekly paclitaxel in previously treated advanced urothelial cancer. J Clin Oncol. 2002; 20: 937940.
  • 12
    Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the PSA Working Group. J Clin Oncol. 1999; 17: 34613467.
  • 13
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 14
    Tannock IF, Osoba D, Stocker MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol. 1996; 14: 17561764.
  • 15
    Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1997; 15: 31563163.
  • 16
    Vaishampayan U, Fontana J, Du W, Hussain M. An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer. Urology. 2002; 60: 10501054.
  • 17
    Hudes GR, Manola J, Conroy J, et al. Phase II study of weekly paclitaxel (P) by 1-hour infusion plus reduced dose oral estramustine (EMP) in metastatic hormone-refractory prostate carcinoma (HRPC): a trial of the Eastern Cooperative Oncology Group [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 175a.
  • 18
    Savarese DM, Halabi S, Hars H, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol. 2001; 19: 25092516.
  • 19
    Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger M. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate cancer. Cancer. 2002; 94: 14571465.
  • 20
    Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol. 1999; 26(5 Suppl 17 ): 1418.
  • 21
    Friedland D, Cohen J, Miller R Jr., et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of bcl-2. Semin Oncol. 1999; 26(5 Suppl 17 ): 1923.
  • 22
    Hudes G, Einhorn L, Ross E, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network Phase III trial. J Clin Oncol. 1999; 17: 31603166.